Succession War at Morgan Stanley?
With James Gorman’s stepping down the battle for succession has officially started. Who will likely take over and what will be the impact on the bank's performance/stock?
Trending Content - Investment Banking Forum
| +203 | Return Rates For Interns Are Falling? | 83 | 2h |
| +128 | UBS Americas IB: The Kids’ Table of Wall Street | 16 | 1d |
| +102 | I am a drunk MD AMA | 38 | 4h |
| +76 | London IB BB is a challenge | 41 | 22h |
| +75 | KISSED MY VP… HELP!!! | 14 | 9h |
| +63 | VP Lifestyle at Top BB Coverage Groups | 40 | 12h |
| +57 | An Outsider’s View of RX Banking Out of College | 6 | 3d |
| +49 | SharePoint makes IB hours HELL | 15 | 3d |
| +48 | UBS Offer Day | 18 | 10h |
| +44 | momentum of Rx groups | 16 | 17h |
Career Resources
More of a succession battle. For serious candidates the war began years ago, presumably. Positioning for this moment doesn't happen overnight.
.
Which will be the next ceo?
bro one started pjt the other now chairs ubs
Ted Pick, Andy Saperstein, or Dan Simkowitz. My money is on Pick.
And it is Pick, you should have bet something on it
Interesting how the succession line up changed the last 3 years or so with Kelleher, Pruzan and Petitgas leaving. My money is on Pick tbf
My money is on Saperstein. It only makes sense. They have been leaning WM heavy so he has that going for him
True, but how much more does he have to prove? And how much more is there for him to do? Does MS want to go that route of being seen as more a WM/IM institution vs investment banking? I see arguments both ways.
I think it has to do more with what the bank identifies as lately, and for MS they have leaned heavy on that WM/IM. And it was a great strategy and helped MS stock outperform some of its competitors. I think it's more of a reward and signal to shareholders to pick the guy in WM. Him being a younger guy will probably help too.
MS will always be known as an Investment bank and legacy clients will always go to them for business. But you can see a big switch in strategy... even this year they are much slower in IBD and trail GS, JPM, BAML in league tables
i'm an MS analyst so obv biased but i'm not quite sure if a YTD league table is the best way to indicate a change in strategy away from IBD. I think MS knows IBD makes money and that the MS name will continue to generate revenue so they'll always invest in it. we aren't a european BB with questionable IBD marketshare in the US.
WM/IM just happened to be a business push that worked well so they'll continue to invest there. think about GS over the last few years, they invested in consumer banking and it went horribly but if it went well, you wouldn't have said "oh well GS is changing its strategy to focus only on consumer banking"
Qui voluptas et iusto delectus. Vitae molestiae adipisci consequatur explicabo. In quas ipsam necessitatibus. Nobis voluptates voluptatem perspiciatis vero et expedita. Quibusdam quia ut minus et.
Illo libero quas velit et et mollitia veritatis. Saepe fugit voluptatem facilis rerum. In nostrum dolorem dolorem nihil autem doloribus culpa perspiciatis. Aut dolores dicta et alias quibusdam porro voluptate officia. Adipisci eligendi et expedita qui nisi dolor quod. Autem nesciunt aut velit fugit ipsum. Et nulla ut placeat non et eos.
Rerum dicta asperiores est fugit velit vel qui. Ut aut veniam rerum et similique aut ut. Repellendus dicta dolores ut nihil qui.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...